2023年3月6日

試驗測量無症狀房顫在老年婦女。總經理邁克爾Barbella Editor03.06.23斯坦福大學醫學研究人員選擇心髒Insight Inc .) Cardea獨奏心電圖可穿戴係統醫學研究心房顫動(房顫)在老年婦女。研究”,連續7天心電圖補丁房顫在高危篩查老年婦女的CHARGE-AF得分,“在老年婦女測量無症狀房顫,條件是增加中風的風險。研究人員想要確定AF檢測到連續的頻率,七天患者的心電圖補丁檢查確認為房顫風險升高。參與者被郵寄Cardea獨奏心電圖(心電圖)補丁監測穿七天並返回進行分析。Cardea獨奏是一個輕量級,防水動態心髒監測係統。心電圖可穿戴傳感器提供了準確的結果使用賁門洞察力的自動心電圖數據分析和報告軟件。PPV Cardea獨奏的心電圖檢測算法有99%(陽性預測值)房顫檢測。另一個因素使得Cardea獨奏適合研究是其人體工學設計,據該公司。Cardea獨奏可支配心電圖生物傳感器沒有電纜和舒適,低調的,鼓勵病人遵守規定穿。“我們很高興研究小組選出標準化Cardea獨奏的研究中,“心髒洞察力CEO最小Kim說。 “In this kind of research, it’s essential to have reliable, accurate results. We are proud of the sensitivity and accuracy of our wearable ECG monitoring system as we designed Cardea SOLO for in-office diagnostic procedures, so extracting patient data is easy and safe.” In addition to AF, Cardea SOLO can detect more than 15 abnormal cardiac rhythms, including ventricular tachycardia, bradycardia, premature atrial contractions (PACs and other potentially serious arrhythmias). Cardiac Insight is a U.S. digital healthcare innovation company developing medical-grade, body-worn sensor technology, and automated cardiac analysis solutions through its proprietary algorithms and software platforms. The company’s products include the Cardea SOLO wearable ECG Sensor and Software Analysis System, and the Cardea 20/20 ECG – the only resting 12-Lead ECG System designed for cardiac risk screening in young athletes at all levels of play.